Neuromodulation Using Ultra Low Frequency Current Waveform Reversibly Blocks Axonal Conduction And Chronic Pain

KEY TAKEAWAYS:

• Novel Ultra Low Frequency (ULF™) neuromodulation inhibits pain signals in pre-clinical animal models, computational models, and in a clinical trial
• The mechanism of ULF™ neuromodulation is unique, enabling controlled and reversible inhibition of pain neurons through sodium channel inactivation. This mechanism of action is different than existing SCS technologies, which work by activating neurons
• In a clinical trial, patients experienced a dramatic decrease in back pain with ULF™ neuromodulation therapy:
  • 95% of patients were responders (≥50% pain relief)
  • 90% of patients were profound responders (≥80% pain relief)
  • Patients experienced 90% reduction in back pain (starting VAS mean of 74.8 mm decreased to 7.6 mm at 15 days, p<0.001)
  • Patients did not experience paresthesia, or loss of sensation or function
• ULF™ neuromodulation has a unique mechanism of action and is a promising, novel treatment for chronic pain